1. Home
  2. REVB vs CHEK Comparison

REVB vs CHEK Comparison

Compare REVB & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • CHEK
  • Stock Information
  • Founded
  • REVB 2020
  • CHEK 2004
  • Country
  • REVB United States
  • CHEK Israel
  • Employees
  • REVB N/A
  • CHEK N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • CHEK Medical Electronics
  • Sector
  • REVB Health Care
  • CHEK Health Care
  • Exchange
  • REVB Nasdaq
  • CHEK Nasdaq
  • Market Cap
  • REVB 3.7M
  • CHEK 4.3M
  • IPO Year
  • REVB N/A
  • CHEK 2015
  • Fundamental
  • Price
  • REVB $0.79
  • CHEK $0.77
  • Analyst Decision
  • REVB
  • CHEK
  • Analyst Count
  • REVB 0
  • CHEK 0
  • Target Price
  • REVB N/A
  • CHEK N/A
  • AVG Volume (30 Days)
  • REVB 3.0M
  • CHEK 19.6K
  • Earning Date
  • REVB 08-08-2025
  • CHEK 08-14-2025
  • Dividend Yield
  • REVB N/A
  • CHEK N/A
  • EPS Growth
  • REVB N/A
  • CHEK N/A
  • EPS
  • REVB N/A
  • CHEK N/A
  • Revenue
  • REVB N/A
  • CHEK N/A
  • Revenue This Year
  • REVB N/A
  • CHEK N/A
  • Revenue Next Year
  • REVB N/A
  • CHEK N/A
  • P/E Ratio
  • REVB N/A
  • CHEK N/A
  • Revenue Growth
  • REVB N/A
  • CHEK N/A
  • 52 Week Low
  • REVB $0.74
  • CHEK $0.56
  • 52 Week High
  • REVB $56.00
  • CHEK $3.04
  • Technical
  • Relative Strength Index (RSI)
  • REVB 26.64
  • CHEK 45.27
  • Support Level
  • REVB $0.74
  • CHEK $0.71
  • Resistance Level
  • REVB $0.88
  • CHEK $0.77
  • Average True Range (ATR)
  • REVB 0.06
  • CHEK 0.03
  • MACD
  • REVB 0.08
  • CHEK -0.00
  • Stochastic Oscillator
  • REVB 32.49
  • CHEK 46.23

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: